Single-agent pembrolizumab (Keytruda) did not meet a prespecified endpoint of superior overall survival compared with chemotherapy as a second- or third-line treatment for patients with metastatic triple-negative breast cancer, missing the primary endpoint of the phase III KEYNOTE-119 trial.
Emil Cohen, MD, discusses the locoregional therapies available for the treatment of patients with hepatocellular carcinoma and offers insight into optimal strategies.
Antonio Passaro, MD, PhD, discusses findings from a phase IIIb trial for patients with EGFR mutation-positive non–small cell lung cancer and discussed results from other studies investigating ALK and KRAS mutations in patients with NSCLC.
Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.
Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.
Danielle M. Brander, MD, discusses the investigational combination treatments that are bringing patients with chronic lymphocytic leukemia one step closer to well-tolerated, time-limited therapy.
Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.
Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.
Lyudmila A. Bazhenova, MD, sheds light on initial treatment approaches for patients with EGFR-mutant NSCLC and adapted therapeutic strategies at the time of progression.
Ivosidenib demonstrated a statistically significant improvement in progression-free survival by independent radiology review compared with placebo in patients with IDH1-mutant previously treated cholangiocarcinoma.
Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.
The European Commission has granted an approval to lenalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for stem cell transplant, as well as pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with myeloma who have received ≥1 prior treatment regimen that included lenalidomide.
The FDA has approved the combination of venetoclax and obinutuzumab for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.
The FDA has approved the combination of avelumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma.
The FDA’s Oncologic Drugs Advisory Committee voted 8-3 against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.
Richard Bold, MD, chief of the Division of Surgical Oncology, has been named Physician-in-Chief of the UC Davis Comprehensive Cancer Center.
The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.
The FDA’s Oncologic Drugs Advisory Committee voted in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor.
The FDA has granted a breakthrough therapy designation to pomalidomide for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.
Bradley McGregor, MD, speaks about the various data that have emerged in renal cell carcinoma with combinations of immunotherapy, TKIs, and how he chooses between the available treatments for his patients.
The FDA has approved ramucirumab (Cyramza) monotherapy for patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/ML and have been previously treated with sorafenib.
Pei-Chun McGregor, MD, discusses where future research with androgen deprivation therapy-associated adverse events is headed, and called for multidisciplinary care for patients receiving this approach.
The combination of nivolumab plus radiation therapy compared with temozolomide did not improve overall survival in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme, missing the coprimary endpoint of the phase III CheckMate-498 trial.
Atish D. Choudhury, MD, PhD, details the advances in metastatic prostate cancer in light of updated analyses from several clinical trials and forthcoming research in the field.
This month, OncLive® officially launched the OncLive® Community, a social network designed specifically for healthcare professionals working in the field of oncology.
Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.
Daphne B. Stewart, MD, highlights the pivotal trials evaluating CDK4/6 inhibitors and what unanswered questions remain with this class of agents.
Guru Sonpavde, MD, discusses the current use of immunotherapy and the numerous strategies in development in bladder cancer.
Lyndsey Runaas, MD, discusses the newfound outlook for patients with FLT3- and IDH1/2-mutant acute myeloid leukemia given recent regulatory approvals and trial data.